Compare ATNM & MLSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATNM | MLSS |
|---|---|---|
| Founded | 2000 | 1989 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 29.2M |
| IPO Year | 2013 | 1996 |
| Metric | ATNM | MLSS |
|---|---|---|
| Price | $1.45 | $0.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $4.00 | $1.25 |
| AVG Volume (30 Days) | ★ 238.5K | 94.7K |
| Earning Date | 11-13-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.17 | N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | $90,000.00 | ★ $8,973,982.00 |
| Revenue This Year | $38,788.89 | $11.14 |
| Revenue Next Year | N/A | $13.80 |
| P/E Ratio | $2.00 | ★ N/A |
| Revenue Growth | ★ 11.11 | 3.99 |
| 52 Week Low | $0.74 | $0.22 |
| 52 Week High | $1.72 | $0.58 |
| Indicator | ATNM | MLSS |
|---|---|---|
| Relative Strength Index (RSI) | 59.32 | 42.09 |
| Support Level | $0.91 | $0.30 |
| Resistance Level | $1.66 | $0.40 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 70.42 | 53.16 |
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.